The short version of HPLC-UV fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-23 and is reviewed periodically as new material appears.
In solid form, creatine monohydrate is relatively stable when kept dry and away from heat. Moisture and elevated temperatures promote cyclization into creatinine, a related compound with no role in the phosphagen system. Degradation accelerates in aqueous solution, where the conversion can occur within hours to days depending on pH and temperature. Manufacturers typically recommend storage in sealed containers at room temperature, with relative humidity below 50 percent. Long-term stability data for opened containers are limited.
Analytical methods for creatine monohydrate focus on identity, purity, and degradation products. High-performance liquid chromatography with ultraviolet detection is common, often at a wavelength near 210 nanometers. Titration and nuclear magnetic resonance spectroscopy can also quantify the parent compound. Pharmacopeial monographs specify tests for appearance, solubility, water content, and related substances, including creatinine. Purity values above 99 percent are typical for pharmaceutical-grade material, though supplement-grade products vary. Independent verification can detect label discrepancies.
In the human body, creatine is synthesized mainly in the liver and kidneys from the amino acids glycine, arginine, and methionine. Dietary sources include meat, fish, and other animal tissues, which supply preformed creatine. Because plant foods contain little or no creatine, dietary intake varies widely among populations. The compound is stored largely in skeletal muscle, where it is converted to phosphocreatine and used to regenerate adenosine triphosphate during short bursts of activity.
Creatine monohydrate is one of several solid forms of creatine described in the literature. Other forms include anhydrous creatine, creatine hydrochloride, and creatine ethyl ester, each with different solubility and stability characteristics. The monohydrate is distinct from creatinine, a spontaneous breakdown compound that forms when creatine loses water and cyclizes. Commercial descriptions sometimes use synonyms such as methylguanidoacetic acid or N-(aminoiminomethyl)-N-methylglycine, which refer to the same base molecule. These names appear in chemical databases and product labels.
Creatine monohydrate is a crystalline compound formed when one molecule of creatine binds with one molecule of water. Creatine itself is a nitrogen-containing organic acid involved in cellular energy transfer, particularly in muscle and nerve tissue. The monohydrate form is the most common solid form used in research and commercial products because it is relatively stable and easy to handle. Its molecular formula is C4H9N3O2·H2O, and its molar mass is about 149.15 grams per mole.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | 15–25 °C | Cool, dry, away from moisture |
| Relative humidity | < 50% | High humidity promotes degradation |
| Primary degradation product | Creatinine | Formed via cyclization, especially in solution |
| Common analytical method | HPLC-UV | Often at 210 nm; also titration or NMR |
| Shelf life (solid) | 2–3 years | When kept sealed and dry; varies by manufacturer |
Solid creatine monohydrate is generally stable when kept dry and protected from extremes of heat and humidity. In the presence of moisture, it can gradually convert to creatinine, a cyclic dehydration product that has little value for phosphocreatine synthesis. Elevated temperatures and acidic conditions accelerate this conversion in solution. Because the reaction is slow in cool, dry storage, typical shelf lives are measured in years rather than weeks. Packaging that limits moisture and oxygen exposure helps maintain purity.
Recommended storage usually involves a sealed container kept at room temperature, away from direct sunlight and moisture. High humidity can cause caking, which changes flow properties and may complicate accurate weighing. Repeated opening of containers exposes the powder to air and moisture, so smaller aliquots can reduce handling effects. Storage temperature ranges are not absolute requirements; they reflect conditions that slow degradation and preserve consistent physical characteristics. Clean, dry tools help prevent contamination during sampling.
Identity and purity are commonly assessed by high-performance liquid chromatography, often with ultraviolet detection, and by spectroscopic techniques such as infrared or nuclear magnetic resonance. These methods can distinguish creatine from creatinine and detect related impurities. Moisture content may be measured by Karl Fischer titration or loss on drying. Particle size, bulk density, and heavy metal limits are additional quality parameters. Not every product is tested by every method, so specifications depend on the intended use and regulatory framework.
Quality control for creatine monohydrate begins with identity confirmation and assay determination. Laboratories commonly use high-performance liquid chromatography with ultraviolet detection, often after derivatization or using a suitable column, to quantify creatine. Karl Fischer titration measures water content, which helps verify the monohydrate stoichiometry. Additional tests screen for heavy metals, residual solvents, and microbial contamination depending on the intended use. These tests establish composition and purity rather than biological effect.
Stability studies examine how creatine monohydrate changes under controlled temperature and humidity. The solid is generally stable when kept dry, but moisture can promote hydrolysis to creatinine, especially in solution or at elevated temperatures. Color, odor, and assay values are monitored over time to detect degradation. Because degradation pathways depend on storage conditions, shelf-life claims should specify the tested packaging, temperature, and humidity. Open questions remain about the long-term behavior of different crystal habits and particle sizes.
Regulatory treatment of creatine monohydrate varies by country and intended use. In some jurisdictions it is sold as a dietary supplement, while in others it may be treated as a food ingredient or a pharmaceutical raw material. Pharmacopeial monographs, where available, define identification, assay limits, and impurity thresholds. Manufacturers often follow these monographs or internal specifications to ensure batch-to-batch consistency. Analytical method validation is important because different methods can yield different apparent purity values if sample preparation or detection conditions are not controlled.
The compound was identified in the nineteenth century after chemists isolated a nitrogenous substance from meat extracts. Later work established its role in muscle energy metabolism and its conversion to phosphocreatine. Chemical synthesis of creatine followed, and industrial production made the monohydrate widely available as a purified powder. Interest expanded in the late twentieth century when researchers began studying creatine supplementation and muscle physiology. Historical accounts sometimes differ on exact dates and attributions, but the broad sequence from tissue extracts to synthetic production is well documented.
In the body, creatine is obtained from dietary meat and fish and is also synthesized from arginine, glycine, and methionine. Muscle stores creatine and phosphocreatine, which participate in the rapid regeneration of adenosine triphosphate during short, intense activity. The monohydrate form is used in research because it is chemically defined, stable as a dry solid, and relatively inexpensive to produce. Questions remain about whether other creatine forms offer meaningful advantages in absorption or tissue retention, and findings vary across studies and populations.
Several creatine forms are sold, including monohydrate, anhydrous, hydrochloride, nitrate, citrate, and blends. Once dissolved, these forms deliver creatine, but they differ in molar mass, solubility, counterions, and water content. Creatine monohydrate has the largest body of published human data among these forms. Questions remain about whether any alternative form offers meaningful advantages in absorption, tolerability, or tissue uptake under practical conditions. The hydrate form's lower creatine content by mass is a compositional fact, not a statement about effectiveness.
Creatine monohydrate is a crystalline compound formed when one molecule of creatine associates with one molecule of water in the solid lattice. Its molecular formula is C4H11N3O3, and its molar mass is about 149.15 grams per mole. The material appears as a white, odorless powder that dissolves sparingly in water at room temperature. The monohydrate designation distinguishes it from anhydrous creatine, which lacks the bound water and has a lower molar mass. This hydrate is the most common commercial form of creatine used in nutritional and research settings.
Creatine is synthesized endogenously in humans, mainly in the liver, kidney, and pancreas, from the amino acids arginine, glycine, and methionine. Skeletal muscle stores much of the body's creatine, where it participates in the phosphocreatine system that buffers adenosine triphosphate during short, intense contractions. Dietary sources include meat and fish, so omnivorous diets provide additional creatine beyond endogenous production. Supplemental creatine monohydrate supplies the same molecule found in food and tissues, not a distinct drug or hormone. Research interest centers on its role in cellular energy transfer and its effects on muscle and other tissues.
=== Ampika's Aesthetics === Pickston is the founder and CEO of Ampika's Aesthetics, a cosmetic training business with schools in Hale, Edinburgh, Bristol, Newcastle and London's Harley Street. It was founded in 2019. The training academy offers aesthetic and cosmetic training for beginners and medical professionals to gain experience and CPD accreditation. It is regulated by OFQUAL through Qualifi.
=== Category:EC 5.2 (cis-trans-isomerases) === Category:EC 5.2 FKBP: FKBP1A FKBP1B FKBP2 FKBP3 FKBP4 FKBP5 FKBP6 FKBP8 FKBP9 FKBP10 FKBPL Cyclophilin Parvulin Prolyl isomerase 2-chloro-4-carboxymethylenebut-2-en-1,4-olide isomerase Beta-carotene isomerase Farnesol 2-isomerase Furylfuramide isomerase Linoleate isomerase Maleate isomerase Maleylacetoacetate isomerase Maleylpyruvate isomerase Parvulin Photoisomerase Prolycopene isomerase Prolyl isomerase Retinal isomerase Retinol isomerase Zeta-carotene isomerase
Many of Pauling's critics, including scientists who appreciated the contributions that he had made in chemistry, disagreed with his political positions and saw him as a naïve spokesman for Soviet communism. In 1960, he was ordered to appear before the Senate Internal Security Subcommittee, which termed him "the number one scientific name in virtually every major activity of the Communist peace offensive in this country". A headline in Life magazine characterized his 1962 Nobel Prize as "A Weird Insult from Norway". Pauling was a frequent target of the National Review magazine. In an article entitled "The Collaborators" in the magazine's July 17, 1962, issue, Pauling was referred to not only as a collaborator, but as a "fellow traveler" of proponents of Soviet-style communism. In 1963, Pauling sued the magazine, its publisher William Rusher, and its editor William F. Buckley, Jr for $1 million. He lost both his libel suits and the 1968 appeal (unlike his earlier 1963 libel case against the Hearst Corporation), because in the meantime the landmark case New York Times Co. v. Sullivan had established the actual malice standard for libel lawsuits by public figures, requiring that not only falsehood but deliberate lying should be proved by the plaintiff in such cases. His peace activism, his frequent travels, and his enthusiastic expansion into chemical-biomedical research all aroused opposition at Caltech. In 1958, the Caltech Board of Trustees demanded that Pauling step down as chairman of the Chemistry and Chemical Engineering Division.
=== Reproduction and development === Sows usually produce their first litter at the age of 3 to 5 years, with those living in more developed areas tending to get pregnant at younger ages. The breeding period usually occurs in the June–July period, though it can extend to August in the species' northern range. The breeding period lasts for two to three months. Both sexes are promiscuous. Males try to mate with several females, but large, dominant ones may violently claim a female if another mature male comes near. Copulation can last 20–30 minutes. Sows tend to be short-tempered with their mates after copulating. The fertilized eggs undergo delayed development and do not implant in the female's womb until November. The gestation period lasts 235 days, and litters are usually born in late January to early February. Litter size is between one and six cubs, typically two or three. At birth, cubs weigh 280–450 g (0.62–0.99 lb) and measure 20.5 cm (8.1 in) in length. They are born with fine, gray, down-like hair and their hind quarters are underdeveloped. They typically open their eyes after 28–40 days and begin walking after 5 weeks. Cubs are dependent on their mother's milk for 30 weeks and will reach independence at 16–18 months. At 6 weeks, they attain 900 g (2.0 lb), by 8 weeks they reach 2.5 kg (5.5 lb) and by 6 months they weigh 18 to 27 kg (40 to 60 lb). They reach sexual maturity at 3 years and attain their full growth at 5 years.
Sources: en.wikipedia.org
2016 With M. M. Rosenberg, M. F. Roberts, and L. Hedstrom. Substrate and cofactor dynamics on guanosine monophosphate reductase probed by high resolution field cycling 31P NMR relaxometry. Journal of Biological Chemistry 291(44):22988–22998.
=== Foundation and early years === Medtronic was founded in 1949 in Minneapolis by Earl Bakken and his brother-in-law, Palmer Hermundslie, as a medical equipment repair shop. Bakken invented several medical technology devices that continue to be used around the world today. Through his repair business, Bakken came to know C. Walton Lillehei, a doctor of heart surgery at the University of Minnesota Medical School. The deficiencies of artificial pacemakers at the time became evident during a power outage over Halloween in 1957, which affected large sections of Minnesota and western Wisconsin. A pacemaker-dependent paediatric patient of Lillehei died because of the blackout. The next day, Lillehei spoke with Bakken about developing some form of battery-powered pacemaker. Bakken modified the design for a transistorized metronome and created the first battery-powered external pacemaker. It fit in a four-inch-square box that could be taped to a patient's chest, transmitted electrical signals to the heart through wires that passed through the patient's chest, and could be removed without surgery.
Transthoracic echocardiography is not recommended in the evaluation of aortic dissections owing to its limited ability to evaluate the aortic arch, the descending aorta or the blood vessels branching from the aorta. Its sensitivity may be further reduced in patients with obesity or lung emphysema. Transthoracic echocardiography has high sensitivity in evaluating the aortic root and proximal ascending aorta. It can also be done at bedside and no sedation is required. It may also identify complications of aortic dissection including heart failure, pericardial effusion with possible cardiac tamponade, and aortic valve regurgitation or other valve disorders. Transesophageal echocardiography has a sensitivity of 96.8% and specificity of 100% in the diagnosis of aortic dissections. It is also able to assess the descending aorta in the thorax. It can also assess the aortic valve and other heart valves, as well as assess the true lumen or false lumin of aortic dissections, which can help guide surgical repair planning and options. Transesophageal echocardiography requires the person to be sedated.
Sources: en.wikipedia.org
=== Oncology === Signatera is the first circulating tumor DNA (ctDNA) assay built for molecular residual disease (MRD) detection and cancer recurrence monitoring. In 2020, Signatera received the CE Mark, as well as final Medicare coverage in stage II-III colorectal cancer and draft coverage in immunotherapy response monitoring. Signatera has been clinically validated to detect colorectal cancer recurrence up to 16.5 months in advance of radiologic imaging and early-stage breast cancer up to two years earlier than imaging.
It is highly efficient. As the figure demonstrates, the number of peptides formed in the synthetic process (3, 9, 27, 81) increases exponentially with the number of executed cycles. Using 20 amino acids in each synthetic cycle, the number of formed peptides are 400, 8,000, 160,000 and 3,200,000, respectively. This means that the number of peptides increases exponentially with the number of the executed cycles. All peptide sequences that are formed in the process can be deduced by a combination of the amino acids used in the cycles. Portioning of the support into equal samples assures formation of the components of the library in nearly equal molar quantities. Only a single peptide forms on each bead of the support. This is the consequence of using only one amino acid in the coupling steps. It is completely unknown, however, which is the peptide that occupies a selected bead. The split-mix method can be used for the synthesis of organic or any other kind of library that can be prepared from its building blocks in a stepwise process. In 1990, three groups described methods for preparing peptide libraries by biological methods and one year later Fodor et al. published a remarkable method for synthesis of peptide arrays on small glass slides. A "parallel synthesis" method was developed by Mario Geysen and his colleagues for preparation of peptide arrays. They synthesized 96 peptides on plastic rods (pins) coated at their ends with the solid support. The pins were immersed into the solution of reagents placed in the wells of a microtiter plate.
== Interactions == Atomoxetine is a substrate for CYP2D6. Concurrent treatment with strong CYP2D6 inhibitors such as bupropion, fluoxetine, paroxetine, and quinidine has been shown to substantially increase atomoxetine exposure, as well as increase N-desmethylatomoxetine levels and decrease 4-hydroxyatomoxetine levels. Bupropion increased atomoxetine exposure by 5.1-fold and decreased 4-hydroxyatomoxetine-O-glucuronide exposure by 1.5-fold. Similarly, paroxetine increased atomoxetine steady-state peak levels by 3.5-fold, total exposure (over 12 hours) by 6.5-fold, and elimination half-life by 2.5-fold. Findings were analogous for fluoxetine and quinidine. CYP2D6 inhibitors do not appear to affect atomoxetine metabolism in CYP2D6 poor metabolizers. Dosage adjustment of atomoxetine may be necessary in people taking strong CYP2D6 inhibitors. Atomoxetine does not show clinically important inhibition or induction of cytochrome P450 (CYP450) enzymes including CYP1A2, CYP3A, CYP2D6, and CYP2C9. It did not affect the pharmacokinetics of the CYP2D6 substrate desipramine, whereas it increased exposure to the CYP3A4 substrate midazolam by only 15%. Atomoxetine is a moderate to potent inhibitor of P-glycoprotein. Other notable drug interactions include:
Sources: en.wikipedia.org
Yes, especially when exposed to moisture or heat, where it converts to creatinine. In dry, sealed containers at room temperature, degradation is slow and the product may remain within specification for two to three years.
Common methods include high-performance liquid chromatography, titration, and nuclear magnetic resonance spectroscopy. These techniques quantify the parent compound and detect related substances such as creatinine.
Keep the powder in a tightly sealed container in a cool, dry place, ideally between 15 and 25 degrees Celsius with low humidity. Avoid storing aqueous solutions for extended periods because degradation occurs faster in solution.
Creatine monohydrate is the hydrated solid form of creatine, a nitrogen-containing compound involved in cellular energy metabolism. It consists of one creatine molecule associated with one water molecule in a crystal lattice.